. 1998 Apr 1;18(7):2498–2505. doi: 10.1523/JNEUROSCI.18-07-02498.1998

Table 2.

Effects of corticosteroids and Ig treatment on remyelination 3 weeks after lysolecithin-induced demyelination in the spinal cord

Treatment	Lesion area^c,d(mm²)	Remyelinated axons^c,e(No./mm² lesion)	G ratio: myelin sheath^f,g thickness/axon diameter (%)
PBS control^2-a	0.131 ± 0.01 (5)	1875 ± 323 (5)	9.6 ± 0.4 (92)
Polyclonal IgG^2-a	0.127 ± 0.03 (4)	2668 ± 506 (4)	9.3 ± 0.6 (74)
Anti-SCH Ig^2-a	0.128 ± 0.02 (5)	3411 ± 593 (5)	8.0 ± 0.5 (69)
MAb SCH 94.03^2-a	0.079 ± 0.02 (4)	3983 ± 627 (4)	8.2 ± 0.5 (76)
Methylprednisolone^2-b	0.087 ± 0.03 (5)	4561 ± 1085 (5)	8.7 ± 0.5 (87)

^F2-a

Treatment given on days 7, 10, 14 and 17 following lysolecithin.

^F2-b

Treatment given on days 0, 3, 7, 10, 14 and 17 following lysolecithin.

^F2-c

Number in parentheses indicates the number of mice examined; data expressed as mean ± SEM.

^F2-d

By ANOVA the size of lesion area was not significantly different between groups (p > 0.05).

^F2-e

By ANOVA the number of remyelinated axons was significantly different between the groups (p < 0.05). Student’s t test showed significant differences between PBS control versus mAb SCH94.03 (p = 0.02) and PBS control versus methylprednisolone (p = 0.02).

^F2-f

Number in parentheses indicates the number of axons remyelinated by oligodendrocytes studied by electron microscopy; data expressed as mean ± SEM.

^F2-g

No significant differences were observed in the G-ratio by ANOVA.